A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Merck Sharp & Dohme LLC
TCR2 Therapeutics
TCR2 Therapeutics
SOLTI Breast Cancer Research Group
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc